Tigermed Reports Full Year 2024 Results
Tigermed (300347.SZ/3347.HK) reported its 2024 annual results with total revenue of RMB 6,603 million, showing a 10.6% YoY decrease. The company's adjusted net profit declined 42.1% YoY to RMB 855 million. However, net new bookings grew 7.3% YoY to RMB 8,423 million, with backlog reaching RMB 15,776 million (+12.0% YoY).
The company maintained its leading position with 12.8% market share in China's clinical CRO market, assisting in 28 Class I new drug and 6 innovative medical device approvals. Clinical Trial Solutions revenue decreased 23.8% YoY to RMB 3,178 million, while Clinical-related and Lab Services revenue increased 6.5% YoY to RMB 3,425 million.
Notable achievements include expanding global presence through acquisitions in Japan and China, launching AI initiatives, and managing 831 ongoing drug clinical trials. The company operates in 33 countries with 10,185 employees globally, including 1,626 overseas staff.
Tigermed (300347.SZ/3347.HK) ha riportato i risultati annuali per il 2024 con un fatturato totale di 6.603 milioni di RMB, mostrando una diminuzione del 10,6% rispetto all'anno precedente. L'utile netto rettificato dell'azienda è calato del 42,1% su base annua, raggiungendo i 855 milioni di RMB. Tuttavia, le nuove prenotazioni nette sono cresciute del 7,3% su base annua, arrivando a 8.423 milioni di RMB, con un portafoglio ordini che ha raggiunto i 15.776 milioni di RMB (+12,0% su base annua).
L'azienda ha mantenuto la sua posizione di leader con una quota di mercato del 12,8% nel mercato CRO clinico in Cina, assistendo nell'approvazione di 28 nuovi farmaci di Classe I e 6 dispositivi medici innovativi. I ricavi delle Soluzioni per Trial Clinici sono diminuiti del 23,8% su base annua, raggiungendo i 3.178 milioni di RMB, mentre i ricavi dei Servizi Clinici e di Laboratorio sono aumentati del 6,5% su base annua, raggiungendo i 3.425 milioni di RMB.
Tra i risultati notevoli vi è l'espansione della presenza globale attraverso acquisizioni in Giappone e Cina, il lancio di iniziative di intelligenza artificiale e la gestione di 831 trial clinici in corso. L'azienda opera in 33 paesi con 10.185 dipendenti a livello globale, di cui 1.626 all'estero.
Tigermed (300347.SZ/3347.HK) informó sus resultados anuales de 2024 con ingresos totales de 6,603 millones de RMB, mostrando una disminución del 10.6% interanual. La utilidad neta ajustada de la empresa disminuyó un 42.1% interanual a 855 millones de RMB. Sin embargo, las nuevas reservas netas crecieron un 7.3% interanual a 8,423 millones de RMB, con un backlog que alcanzó los 15,776 millones de RMB (+12.0% interanual).
La empresa mantuvo su posición de liderazgo con una cuota de mercado del 12.8% en el mercado CRO clínico de China, asistiendo en la aprobación de 28 nuevos medicamentos de Clase I y 6 dispositivos médicos innovadores. Los ingresos de Soluciones para Ensayos Clínicos disminuyeron un 23.8% interanual a 3,178 millones de RMB, mientras que los ingresos de Servicios Clínicos y de Laboratorio aumentaron un 6.5% interanual a 3,425 millones de RMB.
Logros notables incluyen la expansión de la presencia global a través de adquisiciones en Japón y China, el lanzamiento de iniciativas de inteligencia artificial y la gestión de 831 ensayos clínicos en curso. La empresa opera en 33 países con 10,185 empleados a nivel global, incluyendo 1,626 personal en el extranjero.
타이거메드 (300347.SZ/3347.HK)는 2024년 연간 결과를 보고하며 총 수익이 66억 6030만 위안으로, 전년 대비 10.6% 감소했다고 발표했습니다. 회사의 조정된 순이익은 전년 대비 42.1% 감소하여 8억 5500만 위안에 달했습니다. 그러나 순 신규 예약은 전년 대비 7.3% 증가하여 84억 2300만 위안에 달했으며, 백로그는 157억 7600만 위안(+12.0% 전년 대비)에 도달했습니다.
회사는 중국 임상 CRO 시장에서 12.8%의 시장 점유율로 선도적인 위치를 유지하며, 28개의 1급 신약과 6개의 혁신적인 의료 기기 승인을 지원했습니다. 임상 시험 솔루션 수익은 전년 대비 23.8% 감소하여 31억 7800만 위안에 도달했으며, 임상 관련 및 실험실 서비스 수익은 전년 대비 6.5% 증가하여 34억 2500만 위안에 도달했습니다.
주목할 만한 성과로는 일본과 중국에서의 인수를 통한 글로벌 존재감 확대, AI 이니셔티브의 출범, 831개의 진행 중인 약물 임상 시험 관리 등이 있습니다. 회사는 33개국에서 10,185명의 직원을 두고 있으며, 그 중 1,626명이 해외에 있습니다.
Tigermed (300347.SZ/3347.HK) a annoncé ses résultats annuels pour 2024, avec un chiffre d'affaires total de 6 603 millions de RMB, affichant une baisse de 10,6 % par rapport à l'année précédente. Le bénéfice net ajusté de l'entreprise a diminué de 42,1 % par rapport à l'année précédente, atteignant 855 millions de RMB. Cependant, les nouvelles réservations nettes ont augmenté de 7,3 % par rapport à l'année précédente, atteignant 8 423 millions de RMB, avec un carnet de commandes atteignant 15 776 millions de RMB (+12,0 % par rapport à l'année précédente).
L'entreprise a maintenu sa position de leader avec une part de marché de 12,8 % sur le marché des CRO cliniques en Chine, en aidant à l'approbation de 28 nouveaux médicaments de Classe I et de 6 dispositifs médicaux innovants. Les revenus des Solutions d'Essais Cliniques ont diminué de 23,8 % par rapport à l'année précédente, atteignant 3 178 millions de RMB, tandis que les revenus des Services Cliniques et de Laboratoire ont augmenté de 6,5 % par rapport à l'année précédente, atteignant 3 425 millions de RMB.
Parmi les réalisations notables figurent l'expansion de la présence mondiale par le biais d'acquisitions au Japon et en Chine, le lancement d'initiatives d'IA et la gestion de 831 essais cliniques en cours. L'entreprise opère dans 33 pays avec 10 185 employés dans le monde, dont 1 626 à l'étranger.
Tigermed (300347.SZ/3347.HK) hat seine Jahresergebnisse für 2024 veröffentlicht, mit einem Gesamtumsatz von 6.603 Millionen RMB, was einem Rückgang von 10,6% im Jahresvergleich entspricht. Der bereinigte Nettogewinn des Unternehmens sank um 42,1% im Jahresvergleich auf 855 Millionen RMB. Dennoch wuchsen die Nettoneubuchungen um 7,3% im Jahresvergleich auf 8.423 Millionen RMB, während der Auftragsbestand 15.776 Millionen RMB (+12,0% im Jahresvergleich) erreichte.
Das Unternehmen behauptete seine führende Position mit einem Marktanteil von 12,8% im chinesischen klinischen CRO-Markt und unterstützte die Genehmigung von 28 neuen Arzneimitteln der Klasse I sowie 6 innovativen medizinischen Geräten. Die Einnahmen aus klinischen Studienlösungen sanken um 23,8% im Jahresvergleich auf 3.178 Millionen RMB, während die Einnahmen aus klinikbezogenen und Laborservices um 6,5% im Jahresvergleich auf 3.425 Millionen RMB stiegen.
Zu den bemerkenswerten Erfolgen gehören die Expansion der globalen Präsenz durch Übernahmen in Japan und China, die Einführung von KI-Initiativen und die Verwaltung von 831 laufenden klinischen Studien. Das Unternehmen ist in 33 Ländern tätig und beschäftigt weltweit 10.185 Mitarbeiter, darunter 1.626 im Ausland.
- Net new bookings grew 7.3% YoY to RMB 8,423M
- Backlog increased 12.0% YoY to RMB 15,776M
- Clinical-related and Lab Services revenue up 6.5% YoY
- Global expansion through strategic acquisitions in Japan, China, and Italy
- Assisted in 28 Class I new drug and 6 innovative medical device approvals
- Total revenue decreased 10.6% YoY to RMB 6,603M
- Adjusted net profit declined 42.1% YoY to RMB 855M
- Clinical Trial Solutions revenue fell 23.8% YoY
This press release is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2024 annual results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (www.szse.cn) and the Stock Exchange of
All financials disclosed in this document are presented in accordance with China Accounting Standards for Business Enterprises ("CASBE") except for those specifically noted otherwise.
The 2024 Annual Results of the Company has been audited.
Financial Highlights:
- During the reporting period, total revenue achieved
RMB 6,603 million , representing a year-over-year ("YoY") decrease of10.6% . - Adjusted Net Profit Attributable to the Owners of the Company(1) declined by
42.1% YoY toRMB 855 million during the Reporting Period. - Tigermed new bookings returned to steady growth in 2024, with the net new bookings reached
RMB 8,423 million , representing a7.3% YoY increase. The backlog of future contracted revenue reachedRMB 15,776 million , representing a12.0% YoY increase. - Segment revenue generated from Clinical Trial Solutions reached
RMB 3,178 million , reflecting a23.8% YoY decrease. - Segment revenue generated from Clinical-related and Lab Services reached
RMB 3,425 million , marking a6.5% YoY increase.
(1) Net profit attributable to shareholders of the Company after deducting extraordinary gain or loss |
Business Highlights
In 2024, Tigermed further strengthened its innovation-driven strategy, maintaining its leading position in the
In 2024, through the acquisition of Medical Edge in
In the clinical trial solutions field, as of December 31, 2024, Tigermed had 831 ongoing drug clinical trials and 614 ongoing medical device & IVD projects. In 2024, Tigermed regulatory affairs supported 63 MRCT IND applications, added 39 new
In the clinical-related field, as of December 31, 2024, the Tigermed data management & statistical analysis ("DMSA") team had 842 ongoing projects with 407 global clients, and assisted in the commercialization of 15 innovative drugs in both
In the lab services field, as of December 31, 2024, Frontage Holdings, a subsidiary of Tigermed, successfully passed over 220 on-site inspections by China NMPA and the
In 2024, the company made significant progress in its globalization strategy. As of December 31, 2024, Tigermed's cumulative MRCT experience reached 148 projects. The
In 2024, Tigermed advanced from digitalization to intelligence, leveraging technology innovation to break efficiency barriers in traditional clinical trials. Tigermed launched multiple remote intelligent DCT platforms, including a remote monitoring system (CTRM), a subject eligibility discussion system (SEDS), and a safety report distribution and receiving system (Safety Portal). In 2024,
Upholding a win-win collaboration strategy, Tigermed partnered with global stakeholders to optimize resource allocation, earning high recognition from industry peers worldwide. In 2024, Tigermed initiated digital
The company remained committed to corporate social responsibility, maintaining an AA rating in MSCI ESG assessments. Also, Tigermed-Jyton was awarded the "2024 Future Medical Top 100 –Top 5 Best Customer Satisfaction Medical Device CRO" award, and Tigermed's subsidiary Yaxincheng was named as one of the "2024 Recommended Language Service Providers" and "Recommended
Emergency Translation and Language Service Providers."
Management Comments
"In 2024, technological innovation and unmet clinical needs propelled the global biopharmaceutical industry forward, bringing groundbreaking therapies and hope to patients worldwide," said Dr. Xiaoping Ye, Co-Founder and Chairman of Tigermed. "Navigating both opportunities and challenges, Tigermed remains steadfast in its long-term vision, expanding our global presence and enhancing our innovation-driven ecosystem. We remain committed to collaborating with global clients and partners to accelerate pharmaceutical innovation and improve patient outcomes."
Ms. Xiaochun Cao, Co-Founder, Executive Director, and President of Tigermed, stated: "Tigermed strengthens global operations by deepening local expertise and fostering international collaboration to build a more efficient clinical development ecosystem. By leveraging our extensive global network, we optimize operations, accelerate project delivery, and translate innovation into real-world impact. Simultaneously, we drive technological advancements and digital transformation to deploy intelligent solutions that enhance R&D efficiency and fuel global biopharmaceutical progress."
Mr. Hao Wu, Executive Director and Co-President of Tigermed, remarked: "In response to the rapidly evolving global R&D landscape, Tigermed remains committed to refining our integrated service ecosystem to meet clients' diverse needs. In 2024, we further strengthened our end-to-end capabilities, delivering tailored solutions that enhance R&D speed and competitiveness. Moving forward, we will drive service innovation forward, co-create value with global partners, and ensure that more patients worldwide benefit from medical advancements."
(2) Source: Frost & Sullivan |
Forward-Looking Statements
The information communicated herein may contain certain "forward-looking statements", which are not historical facts but instead include predictions about future events based on our beliefs and information currently made available to us. Although we believe that these predictions are reasonable on the date hereof, future events are inherently uncertain and these forward-looking statements may turn out to be incorrect. Forward-looking statements involve risk and uncertainty by nature because they relate to events and will depend on circumstances that will occur in the future relating to, inter alia, our ability to compete effectively, our ability to develop and market new service offerings, our ability to expand into new markets, the risks associated with listed subsidiaries of the Company, unforeseeable international tensions, regulatory or governmental scrutiny in certain countries, the impact of emergencies and other force majeure events. We undertake no obligations to update forward-looking statements or to adapt them to future events or developments except as required by applicable laws or listing rules. Any investment in any securities issued by the Company or its subsidiaries will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, you should not rely on these forward-looking statements.
About Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,200 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across
View original content:https://www.prnewswire.com/news-releases/tigermed-reports-full-year-2024-results-302413086.html
SOURCE Tigermed
FAQ
What were Tigermed's (HNGZY) key financial results for 2024?
How many ongoing clinical trials did Tigermed manage in 2024?
What was Tigermed's market share in China's clinical CRO market for 2024?
How did Tigermed's Clinical Trial Solutions segment perform in 2024?
What acquisitions did Tigermed complete in 2024?
